Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study

Sun, F; Li, Y; Chen, Y; Guan, WL; Jiang, XG; Wang, XM; Ren, PF; Li, JL; Shi, JC; He, GQ; Wu, MY; Tang, PJ; Wang, F; Sheng, YF; Huang, FL; Zhou, ZM; Huang, HQ; Hong, L; Liu, QH; Zhang, Y; Zhang, WH

Zhang, WH (reprint author), Huashan Hosp, Room 501,Bldg 5,12,Middle Wulumuqi Rd, Shanghai, Peoples R China.

EUROPEAN RESPIRATORY JOURNAL, 2019; 53 (3):

Abstract

The current treatment for multidrug-resistant tuberculosis (MDR-TB) takes a lengthy period of 18-24 months and has a poor cure rate of 50-60%. A multi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索